Azenkot Tali, Jonas Brian A
Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA.
Division of Cellular Therapy, Bone Marrow Transplant, and Malignant Hematology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA.
Cancers (Basel). 2022 Jul 26;14(15):3634. doi: 10.3390/cancers14153634.
Measurable residual disease (MRD) has emerged as a primary marker of risk severity and prognosis in acute myeloid leukemia (AML). There is, however, ongoing debate about MRD-based surveillance and treatment. A literature review was performed using the PubMed database with the keywords MRD or residual disease in recently published journals. Identified articles describe the prognostic value of pre-transplant MRD and suggest optimal timing and techniques to quantify MRD. Several studies address the implications of MRD on treatment selection and hematopoietic stem cell transplant, including patient candidacy, conditioning regimen, and transplant type. More prospective, randomized studies are needed to guide the application of MRD in the treatment of AML, particularly in transplant.
可测量残留病（MRD）已成为急性髓系白血病（AML）风险严重程度和预后的主要标志物。然而，关于基于MRD的监测和治疗仍存在争议。使用PubMed数据库对近期发表期刊中以MRD或残留病为关键词进行了文献综述。已识别的文章描述了移植前MRD的预后价值，并提出了量化MRD的最佳时机和技术。几项研究探讨了MRD对治疗选择和造血干细胞移植的影响，包括患者的入选资格、预处理方案和移植类型。需要更多前瞻性、随机研究来指导MRD在AML治疗中的应用，尤其是在移植方面。
